Pharma BD Deal Intelligence
Coelacanth's chemistry platform became Lexicon's only drug engine and did yield two FDA approvals, but neither became a commercial blockbuster, and the deal's own $32M price is dwarfed by decades of value destruction elsewhere in Lexicon's business.
Full analysis, sources & comparables →Lexicon Genetics said it would acquire Coelacanth Corp. in a deal valued at about $32 million, reflecting Lexicon's efforts to build its drug discovery…
Lexicon purchased a privately owned small chemical library synthesis company, Coelacanth Corporation in Princeton, New Jersey, which became the site for the…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Stock-for-stock; created Lexicon Pharmaceuticals. Below $250M threshold but strategically notable: chemistry/ADME platform; Coelacanth clients included Pfizer, Roche, Novartis.
Coelacanth's chemistry platform became Lexicon's only drug engine and did yield two FDA approvals, but neither became a commercial blockbuster, and the deal's own $32M price is dwarfed by decades of value destruction elsewhere in Lexicon's business.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Lexicon Genetics Incorporated / Coelacanth Corporation (this deal) | 2001 | $32M | 53 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
← Browse all deals · How we score deals
More: 2001 deals